Skip to content

An Evaluation of a Non-invasive Brain Monitor

An Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Brain Monitor

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02775136
Enrollment
160
Registered
2016-05-17
Start date
2014-10-31
Completion date
2017-12-31
Last updated
2019-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries, Brain Neoplasms, Hydrocephalus, Subarachnoid Hemorrhage, Vasospasm, Intracranial

Keywords

brain injuries, neurological monitoring

Brief summary

HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians. Investigators hypothesis that the HS-1000 is capable of detecting and monitoring various neuropathologies, using the acoustic raw data derived from the noninvasive procedure.

Detailed description

Non-invasive modality for brain monitoring can potentially serve as a major contribution to conventional monitoring techniques for patients with neuropathologies, to assure minimal discomfort to the bedbound patients, and provide information about critical physiological signs to the physicians. The lack of a precise diagnostic technique for numerous neuropathologies for patients in neurosurgical clinics can further hinder therapeutic effectiveness and, therefore, influence patient recovery and healing. Neuro-critical care involves monitoring standard vital signs and cerebral physiological signs, mainly focusing on intracranial pressure (ICP), temperature, cerebral blood flow velocity, arterial blood pressure, cerebral perfusion pressure, brain tissue oxygenation etc. The collaboration of state of the art brain monitoring vary between different intensive care units serves a significant drawback in some cases, as accuracy of diagnosis and monitoring is challenged and thereby there is an eminent need for interrelationship brain monitoring approach. That can also be leveraged by applying the monitoring noninvasively, as it particularly beneficial for clinical applications that routinely require the inevitable and dynamic transport of patients between hospital units (imaging, surgical room, etc.). Subjects who meet the inclusion and exclusion criteria for this study, with a signed informed consent form, will be enrolled into the study. Eligible patients will be divided to 2 groups: 1. Patients undergoing Invasive ICP monitoring 2. Subarachnoid hemorrhage (SAH) patients with Fisher Grade of 3 or 4 The non-invasive measurements recording sessions will be according to the protocol scheme per each group: 1. Eligible patients undergoing Invasive ICP monitoring will be monitored by the HS-1000, in parallel to the invasive ICP monitor, for a single recording session. 2. Eligible SAH patients with Fisher Grade of 3 or 4 will be monitored by the HS-1000, in parallel to the invasive ICP monitor, for three recording sessions. For all eligible patients, non-invasive measurements by the HS-1000 device will be conducted in parallel with the standard monitoring modalities, as used at the site without any change in the patient's management.

Interventions

Sponsors

Klinikum Stuttgart
CollaboratorOTHER
Klinikum Darmstadt
CollaboratorOTHER
University Medical Center Goettingen
CollaboratorOTHER
HeadSense Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult men and women subjects, aged 18 years old and over at screening visit 2. Subjects with neuropathology that the principal investigator considers including in this study. 3. Survival expectancy greater than 72 hours 4. Subject or legal authorized representative (per local regulation) is able and willing to comply with the requirements of the protocol 5. Subject or legal authorized representative (per local regulation) is able to understand and sign written informed consent to participate in the study

Exclusion criteria

1. Local ear infection 2. Known allergy or hypersensitivity to any of the test materials or contraindication to test materials 3. For women of childbearing potential: pregnancy (positive pregnancy test) or breast-feeding 4. Subarachnoid hemorrhage (SAH), Fisher Grade 4 5. Subjects currently enrolled in or less than 30 days post-participation in other investigational device or drug study(s), or receiving other investigational agent(s) 6. Any condition that may jeopardize study participation (e.g., abnormal clinical or laboratory finding) or interpretation of study results, or may impede the ability to obtain informed consent (e.g., mental condition)

Design outcomes

Primary

MeasureTime frameDescription
Number of recordings that correlate to neuropathologyup to 1 hourDemonstrate the HS-1000 performance and accuracy in brain monitoring

Secondary

MeasureTime frame
Incidence of adverse events48 hours from the end of monitoring with the HS-1000
Rate of ear infections/irritations graded by none/mild/moderate and severe48 hours from the end of monitoring with the HS-1000

Countries

Germany

Contacts

Primary ContactThomas Swanson
thomas@head-sense-med.com
Backup ContactDana Hromyak
dana@head-sense-med.com216-526-8534

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026